Projects
CARGO: advancing chimeric antigen receptor T cell therapy using nanobody-displaying lentiviral vectors Vrije Universiteit Brussel
However, similar results have not been obtained in the context of solid tumors. Among the top priorities to develop an affordable and ...
ExoRAS: Manipulating exosomes involved in intercellular communication to apply KRAS-targeting and overcome drug resistance in multiple myeloma. KU Leuven
The hematological malignancy multiple myeloma (MM) manifests itself by an accumulation of plasma cells, primarily in the bone marrow. The disease is incurable, as patients in remission tend to develop a tumor that is resistant to all drugs. A major contributor in the development of drug resistance is the RAS family of proteins, which is mutated in ±50% of all human cancers, leading to tumor aggressiveness and growth. These oncogenes were the ...
Gasping for air in the leukemic bone marrow: improving the functioning of natural killer cells in hypoxia. University of Antwerp
PBMC service laboratory. University of Antwerp
PRINT-4-POCT: Rapid prototyping of millifluidic devices for Point-of-Care testing applications. University of Antwerp
The role of SOX11 in T-ALL Ghent University
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological neoplasm with poor outcome for patients with primary resistant or relapsed disease. We have identified T-ALL patients with elevated levels of SOX11 (SOX11 high), a factor that is normally not expressed in normal T-cells, suggesting that SOX11 might have oncogenic potential in T-ALL. Interestingly, SOX11high T-ALL is mostly restricted to theTAL/LMO genetic subgroup and ...
Evaluation of an anti-idiotype NanoCAR-T cell approach for the treatment of Multiple Myeloma Ghent University
Multiple Myeloma (MM) is the 2nd most common hematological disorder and is characterized by accumulation of neoplastic plasma cells in the bone marrow Despite significant therapeutic advances, the majority of patients inevitably relapse due to an incomplete eradication of residual cancer cells MM could be an ideal tumor for immunotherapy as cancer cells express a unique idiotype antigen on the cell surface, a feature that is shared with ...
The role of TET2 in (pre)-leukemic T-cell acute lymphoblastic leukemia Ghent University
T-cell acute lymphoblastic leukemia (T-ALL) is a rare but aggressive subtype of leukemia affecting the T-cell lineage During the malignant transformation of T-cells, a clonal expansion of immature cells is selected for via the gradual accumulation of advantageous epigenetic changes and genetic mutations Long-lived pre-leukemic stem cells (pre-LSCs) were uncovered as an initiating event in various bloodborn cancers, recently also in mouse ...